IOMED, a leader in AI-powered technology for healthcare data activation, has recently announced the closure of a Series A investment round for a total of €10 million. The round was led by Philips Ventures, the venture capital group of health technology leader Philips, and XTX Ventures, the venture capital arm of leading algorithmic trading company XTX Markets. Fondo Bolsa Social and Redseed also participated in the round, as well as IOMED’s existing investors Adara Ventures and EASO Ventures. The company has also received a grant of nearly €1 million from red.es to support a research and development project in artificial intelligence.
This milestone represents the consolidation of the company as a leader in the healthcare technology sector and clear evidence of its unique value proposition. This funding round will enable IOMED to expand internationally, consolidate its position in the current market, and fortify the foundations for the company’s sustainable growth.
Founded in 2016, IOMED develops AI-powered technology for healthcare data activation, which unlocks data from hospitals’ data sources. Its technology activates data from both structured and unstructured sources, thanks to their Natural Language Processing System. This data is transformed into OMOP Common Data Model, and never leaves hospital facilities, thanks to their Federated Data Model. Thus, IOMED is the strategic ally for achieving a healthcare ecosystem driven by Real-World Data.
Javier de Oca, Co-Founder, and CEO of IOMED, added, “At IOMED, our mission is to be the catalyst that drives a better future for the healthcare ecosystem through the application of Artificial Intelligence.”
To achieve these objectives, IOMED has recently consolidated a strategic team in both business and technological development areas to help lead the company during this next stage of growth. Pedro Cladera, who has a solid track record working in major companies such as KPMG and Vueling, Montserrat Roura, who has over 17 years of experience previously working for Novartis, and Antoni Mallol, with more than 30 years of experience in the healthcare sector.
The IOMED brand has also evolved, with an updated brand image that reflects the maturity of the company, its cutting-edge approach, and continuous commitment to excellence and innovation in the healthcare sector. With this investment round and focus on international expansion, IOMED solidifies its position as a reference in the field of artificial intelligence and innovation, positioning itself as a key ally in transforming the healthcare ecosystem.
